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Summary A phase 11 trial of continuous oral therapy with UFT, a combination of uracil and the 5-
fluorouracil analogue 1-(2-tetrahydrofuryl)-5-fluorouracil (Futraful, Ftorafur), was conducted in 40 patients
with advanced colorectal cancer and 18 patients with advanced gastric cancer. Six partial responses were seen
in the 36 evaluable patients with colorectal cancer (response rate 16.6%; 95% confidence limits 6.4-32.8%),
and one partial response was seen in the 16 evaluable patients with gastric cancer (response rate 6%; 95%
confidence limits 0.27-30.2%). The overall toxicity of the treatment was low, and all patients were treated as
outpatients. The results suggest that oral UFT has comparable activity to standard regimes of 5-fluorouracil,
and because of the convenience of oral administration is a useful therapy in the management of patients with
advanced colorectal cancer.
The fluoropyrimidines, particularly 5-fluorouracil (5-FU),
have been widely used as single agents in the therapy of
advanced gastric and colonic cancer. The reported response
rates for these tumours with standard schedules of 5-FU
generally range from 7 to 25% (Moertel, 1973; Earl et al.,
1984). The response to 5-FU appears to be dose and schedule
dependant (Ansfield et al., 1977), and on theoretical grounds,
it would seem that prolonging exposure of tumour cells to
5-FU, would allow the drug to kill more tumour cells as they
enter S phase (Drewinko et al., 1985). Two limitations to the
effective use of 5-FU are its short half-life (approximately
10 min), and its propensity to cause myelotoxicity at higher
doses. Recent approaches that have been taken to enhance its
effectiveness bearing these theoretical limitations in mind, are
the use of continuous infusion therapy (Lokich et al., 1989),
and combining 5-FU with high dose folinic acid (Erlichman
et al., 1988).
Another approach to improve the anti-tumour effects of
fluoropyrimidines that has been described in in vitro test
systems and experimental animal models, is the concomitant
use of purine and pyrimidine nucleotides with fluoropy-
rimidines, e.g. the 5-FU analogue, 1-(2-tetrahydrofuryl)-5-
fluorouracil (Futraful, Ftorafur) (Fujii et al., 1978, 1979). An
enhanced antitumour effect is seen with Futraful if uracil is
concomitantly administered in a molar ratio of 1:4 (Fut-
raful:uracil). The mechanism of this potentiation is thought
to be due to the inhibitory effect of uracil on the degradation
of 5-FU released as a consequence of Futraful metabolism.
The inhibitory effect of uracil on 5-fluorouracil metabolism
seems to be more marked in tumours compared to normal
tissues. Animal (Fujii et al., 1980), and human studies (Tag-
uchi et al., 1978), have shown that the tumour levels of
5-fluorouracil achieved after concomitant administration of
uracil with Futraful are higher than levels in peripheral blood
and that these are sustained for longer periods in tumour
cells.
Futraful has attracted interest not only because of its lower
myelotoxicity, but also because of its greater bioavailability
after oral administration in comparison to 5-fluorouracil. It
is metabolised to 5-fluorouracil and at least four other com-
pounds (Blokhina et al., 1972; Au et al., 1979), which may
also contribute to its cytotoxic effects. The parent compound
has a long half-life, ranging from 6 to 16 h, and may
therefore act as a depot preparation of 5-fluorouracil. In two
studies, comparable plasma levels of 5-fluorouracil over a
period of 24 h were obtained following a 30 min infusion of
Futraful (2 gm-2), and a continuous infusion of 5-
fluorouracil (30 mg kg-', 24 h-') (Anttila et al., 1983;
Chabner, 1982).
These studies suggest that combined administration of
uracil with Futraful might not only enhance antitumour
activity, but also decrease systemic side effects. The results of
a phase II trial of continuous daily administration of an oral
preparation of Futraful and uracil (molar ratio 1:4), known
as UFT, in patients with advanced colorectal and gastric
carcinoma are reported here.
Methods
Drug administration
Phase I trials of UFT have established that the maximum
tolerated dose is in the range of 12 mg kg-' day-' (Taguchi
et al., 1990). In this trial the dose given to patients was
calculated on this basis, and given as three divided doses
daily. In practice most patients received 600 mg UFT day-'
(200 mg three times a day). Treatment was continued for at
least three months, unless there was unequivocal disease
progression or toxicity prior to formal radiological assess-
ment of disease.
Patients
The inclusion criteria for patients were as follows. (1) Patho-
logically confirmed diagnosis of metastatic colorectal or gas-
tric cancer. (2) No prior chemotherapy in the three month
period preceeding entry into the study. (3) No radiotherapy
to sites of evaluable disease. (4) Evaluable disease in two
dimensions as determined radiologically (CT Scan, Ultra-
sound). (5) Karnofsky performance status of 60 or greater.
(6) Normal renal and hepatic function tests (unless due to
disease), and adequate haemopoetic function (white cell
count >4 x 109 1-', platelet count > 100 x 109 1-1).
Evaluation
All patients were examined clinically prior to entry into the
study. Baseline investigations included a full blood count,
estimation of serum electrolytes, urea, creatinine, calcium,
phosphate, bilirubin, alkaline phosphatase, SGOT, total pro-
teins and albumin, and carcinoembryonic antigen. Evaluable
disease was established by computerised axial tomography,
or other appropriate investigations, e.g. ultrasound and chest
radiographs.
Patients were evaluated clinically at 2 week intervals for
the first month after commencing treatment, and monthly
thereafter, with routine blood tests at each visit. Unless there
was unequivocal disease progression or dropout due to drug
toxicity, radiological re-evaluation of disease status was con-
ducted at 3 monthly intervals. Standard WHO response
criteria were used to assess response to treatment (WHO,
1979).
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The details of the patients entered into the study are
shown in Table I.
Table I Patient details
Colorectal cancer Gastric cancer
Total number of patients 40 18
Evaluable 36 16
Sex
Male 27 14
Female 13 4
Age (years)
Mean 59 63
Range (32-79) (28-78)
Karnofsky performance status
Mean 85 80
Range (70-100) (70-100)
Sites of disease
Liver 30 11
Abdo/pelvis 12 13
Lung 6 0
Other 3 1
Previous chemotherapy 3 1
Previous radiotherapy 3 0
Results
Treatment duration
The median duration of treatment in the colorectal cancer
patients was 10 weeks (range 1-132 weeks), and 6 weeks
(range 2.5-40 weeks) in patients with stomach cancer. Treat-
ment discontinuation in all but two patients was due to
progressive disease. These two patients who came off treat-
ment due to toxicity were in the colorectal cancer group, and
stopped treatment at 4 weeks (skin rash), and 32 weeks
(peripheral neuropathy, hand-foot syndrome) respectively. A
total of four (one toxicity, three progressive disease) patients
in the colorectal cancer cohort, and two patients (progressive
disease) in the gastric cancer cohort were unassessable be-
cause they completed less than four weeks of treatment.
Respon.se to treatment
No complete responses were seen in either the colorectal
cancer or gastric cancer groups. There were six partial res-
ponses (16.6%; 95% confidence limits 6.4-32.8%) in the
colorectal cancer group (Table II). The duration of response
shown is from the time of formal assessment at 12 weeks and
may therefore underestimate the actual duration of res-
ponses. All but one patient relapsed at the original metastatic
site. Patient 2 had a sustained partial response in lung and
liver metastases, but relapsed with histologically documented
disease in the inguinal, supraclavicular, and mediastinal
nodes. Patient 4 had to come off treatment due to toxicity
(hand-foot syndrome and peripheral neuropathy). The me-
dian survival in the colorectal cancer patients was 34 weeks.
No responses were seen in the previously treated patients.
There was only one partial response in the gastric cancer
group, given a partial response of 6% (95% confidence limits
0.27-30.2%). This previously untreated patient had inop-
erable stomach cancer, because of disease extension behind
the stomach. After 16 weeks of treatment with UFT, marked
reduction of the abdominal disease was documented radio-
logically, and the patient was able to undergo a total gastrec-
Table II Details of patients with colorectal cancer responding to
UFT
Patient Site of disease Response duration Site ofrelapse
I Liver 24 weeks Liver
2 Lung and liver 40 weeks Lymph nodes
3 Liver 3 weeks Liver
4 Lung and liver >20 weeks Offtreatment due to
toxicity at 32 weeks
5 Liver 24 weeks Liver
6 Liver 9 weeks Liver
tomy. Pathological examination of the stomach revealed
extensive fibrosis, with viable tumour present. The patient
continued UFT, and remained well until 7 months after
gastrectomy, when he was admitted with septicaemia and
died. There was no evidence clinically of tumour, and his
haematological indices did not suggest myelosuppression due
to UFT. A post mortem was not held. The median survival
in the gastric cancer group was 12 weeks.
Toxicity
Gastrointestinal toxicity Mild nausea and vomiting was ex-
perienced by five patients at the start of treatment, but
resolved with continuation of treatment. One patient had
nausea and vomiting requiring treatment discontinuation
temporarily. Two patients experienced diarrhoea, and in one
patient this was severe enough to require cessation of treat-
ment temporarily. UFT was restarted at 400mg day-', and
then increased to 600 mg day-' in this patient, and diarrhoea
did not recur. Stomatitis was not seen in any patient.
Skin Skin toxicity was seen in six patients (16.6%). All of
these patients developed itchy maculopapular eruptions on
the trunk and forearms. In one patient the rash developed at
4 weeks and required treatment discontinuation. Treatment
was not restarted in this patient because of disease progres-
sion. In the other patients, skin rashes developed after more
than 12 weeks of treatment, and in two patients have per-
sisted, although with improvement, despite treatment discon-
tinuation for over 3 months. One of these patients has also
developed marked skin pigmentation. One patient developed
mild alopecia.
Neurotoxicity Two patients (5%) developed symptoms and
signs of peripheral neuropathy at 32 and 36 weeks after
commencing UFT. One of these patients also had signs of
cerebellar dysfunction, which abated after cessation of treat-
ment. Both these patients concomitantly developed the hand-
foot syndrome. In both patients, this has abated following
treatment discontinuation.
Haematological toxicity None of the patients had any evi-
dence of treatment related anaemia or myelosuppression dur-
ing treatment lasting up to 132 weeks. Of the 20 patients
continuing therapy for 12 weeks or more, nine (45%) devel-
oped macrocytosis with normal serum and red cell folate,
and serum vitamin B12 levels. Twenty-one patients (58%)
had mild falls in their platelet counts at 4 weeks after starting
therapy with none of these developing a platelet count less
than 120 x 10 1-'. One patient developed a platelet count of
40 x 1091-' at 132 weeks of treatment, and treatment was
discontinued. A bone marrow examination revealed mild
decrease in cellularity. The platelet count in this patient
continues to be low (60 x I0'1-'), 6 months after stopping
UFT.
Renal and hepatic toxicity None of the patients in the trial
had any evidence of treatment related liver or renal toxicity.
Discussion
The overall prognosis for patients with advanced colorectal
and gastric cancer remains poor, despite improvements in the
response rates achieved with fluoropyrimidines by modifying
administration schedules, and combining treatment with
agents such as folinic acid and alpha-interferon (Wadler et
al., 1989). These regimes, although leading to complete res-
ponses in a small number of patients, are associated with
appreciable toxicity, and require parenteral administration.
The results presented in this paper suggest that oral UFT
is a relatively non-toxic chemotherapeutic agent that has
some efficacy in the treatment ofmetastatic colorectal cancer,
but a dissapointingly low rate of response in gastric cancer.PHASE II TRIAL OF UFT 1025
The observed response rate of 16.6% (95% confidence limits
6.4-32.8%), accurately documented with CT scanning of
measurable disease, is within the range reported for standard
bolus regimes of 5-FU, but lower than that observed with
infusional 5-FU (Lokich et al., 1989), or the combination of
5-FU with high dose folinic acid (Erlichman et al., 1988).
Although these regimes have led to complete remissions in a
very small number of patients, they are associated with
greater toxicity than UFT and for the majority of patients
have no impact on survival. There is therefore still a need for
a chemotherapeutic agent, which can be given with palliative
intent, with a significant antitumour effect, ease of adminis-
tration, and relatively few side effects. This study suggests
that oral administration of UFT may fulfil some of the above
criteria.
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